BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 28, 2026
See today's BioWorld Asia
Home
» Swedish Dilafor extends reach to Asia in deal with Lee’s for obstetrics drug candidate
To read the full story,
subscribe
or
sign in
.
Swedish Dilafor extends reach to Asia in deal with Lee’s for obstetrics drug candidate
Feb. 26, 2014
By
Cornelia Zou
HONG KONG – Stockholm-based Dilafor AB inked a licensing agreement for its tafoxiparin, a drug designed to prevent protracted labor, with Hong Kong’s Lee’s Pharmaceutical Holdings Ltd. (HK:0950).
BioWorld Asia
